Reform Marijuana Laws NORML Site Map Contact Us About Marijuana Law Reform Media Contact About Marijuana Law Reform Home
Working to reform marijuana laws
search by
Click here to navigate by map
State Laws | Leyes Estatales
 
 
 
 
 
Get NORML's eZine
Legislative Alerts, News & Analysis from NORML

Details & Privacy


Get NORML's eZine
Meet Others, Share Stories
 

Home > News Archive > 2009 > Marijuana Use Associated With 'Improved Neurocognition' In Bipolar Patients, Study Says

Marijuana Use Associated With 'Improved Neurocognition' In Bipolar Patients, Study Says

Share This Page Share This Page on digg Share This Page on Reddit Share This Page on del.icio.us Share This Page on Stumble Upon Share This Page on Facebook Share This Page on Twitter Check our RSS Feeds

November 25, 2009 - Oslo, Norway

Oslo, Norway: Cannabis use is associated with "improved neurocognition" in subjects diagnosed with bipolar disorder, according to clinical trial data published online by the journal Psychological Medicine.

Investigators at Norway's University of Oslo, Institute of Psychiatry investigated the association between cannabis use and neurocognition in 133 patients with bipolar disorder. Researchers reported that subjects who used cannabis performed better than non-users on a series of neurocognitive tests. Authors determined that marijuana use was associated with "statistically significant" improvement in attention, executive function, verbal fluency, logistical memory-learning, and logical memory-recall.

Researchers reported that contrasting results were associated with the use of marijuana among subjects diagnosed with schizophrenia.

Investigators concluded, "The findings suggest that cannabis use may be related to improved neurocognition in bipolar disorder and compromised neurocognition in schizophrenia."

The findings conflict with those of a 2007 study published in the journal Progress in Neuro-Psychopharmacology & Biology Psychiatry that reported that cannabis use was not associated with a decline in cognitive function in schizophrenic patients, and might even improve it.

For more information, please contact Paul Armentano, NORML Deputy Director, at: paul@norml.org.

    updated: Nov 25, 2009

Share This Page Share This Page on digg Share This Page on Reddit Share This Page on del.icio.us Share This Page on Stumble Upon Share This Page on Facebook Share This Page on Twitter Check our RSS Feeds

2009   2008   2007   2006   2005   2004   2003   2002   2001   2000   1999   1998   1997   1996  
Country State/Prov Year Month
Join the NORML Legal Committee
Features
Features
   
NORML
Site MapContact UsSupport NORMLTake ActionLibrary
© 2009 NORML • Privacy StatementSite Terms • Site by Communicopia and Red Aphid
NORML and the NORML Foundation: 1600 K Street NW, Suite 501, Washington DC, 20006-2832
Tel: (202) 483-5500 • Fax: (202) 483-0057 • Email: norml@norml.org